Swiss National Bank Lowers Stock Holdings in Hologic, Inc. $HOLX

Swiss National Bank cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 5.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 642,340 shares of the medical equipment provider’s stock after selling 36,900 shares during the period. Swiss National Bank’s holdings in Hologic were worth $43,352,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Winnow Wealth LLC acquired a new stake in shares of Hologic during the third quarter worth $26,000. Root Financial Partners LLC acquired a new position in Hologic in the third quarter valued at $27,000. SJS Investment Consulting Inc. increased its stake in Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Hologic by 168.5% during the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 310 shares during the period. Finally, Loomis Sayles & Co. L P purchased a new position in Hologic during the second quarter worth about $33,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of Hologic stock opened at $75.22 on Friday. The business’s fifty day moving average price is $75.12 and its 200 day moving average price is $72.58. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $75.75. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $16.79 billion, a P/E ratio of 31.34, a PEG ratio of 2.24 and a beta of 0.73.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.87 earnings per share. As a group, research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on HOLX. Evercore cut Hologic from an “outperform” rating to an “in-line” rating and lowered their price target for the company from $79.00 to $78.00 in a report on Monday, January 5th. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research report on Friday, November 21st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Two research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $78.42.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.